Collegeville, PA, United States of America

Lamont Roscoe Terrell

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 7.1

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • King of Prussia, PA (US) (2015)
  • Collegeville, PA (US) (2020 - 2022)

Company Filing History:


Years Active: 2015-2022

Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: **Lamont Roscoe Terrell: Innovator in TRPV4 Antagonists**

Introduction

Lamont Roscoe Terrell is an accomplished inventor based in Collegeville, Pennsylvania. With a total of four patents to his name, Terrell has made significant contributions in the field of pharmaceutical research, particularly focusing on TRPV4 antagonists. His inventions are aimed at enhancing the effectiveness of medications that target specific neurological and pathophysiological conditions.

Latest Patents

Among his latest patents, Terrell has developed innovatively designed pyrrolidine sulfonamide analogs, which are utilized as TRPV4 antagonists. The present invention describes not only these analogs but also the pharmaceutical compositions containing them and their potential applications in therapeutic treatments.

Career Highlights

Throughout his career, Terrell has worked with notable organizations in the pharmaceutical industry. He has had key roles at GlaxoSmithKline Intellectual Property (No.2) Limited and GlaxoSmithKline Intellectual Property Development Limited, where he contributed to the advancement of drug development and intellectual property strategies.

Collaborations

In his professional journey, Terrell has collaborated with esteemed colleagues such as Edward J. Brnardic and Carl A. Brooks. These partnerships have fostered an environment of innovation, leading to breakthroughs in the pharmaceutical domain and enriching the scientific community’s understanding of TRPV4 antagonists.

Conclusion

Lamont Roscoe Terrell exemplifies the spirit of innovation within the pharmaceutical industry. His extensive research and patent portfolio signify his commitment to improving healthcare outcomes through novel therapeutic strategies. As he continues to explore the potential of TRPV4 antagonists, his work remains a testament to the powerful impact of dedicated inventors on society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…